The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
5-(benzo[d][1,3]dioxol-5-ylmethylene)-1-benzylpyrimidine-2,4,6(1H,3H,5H)-trione ID: ALA3261357
PubChem CID: 2272071
Max Phase: Preclinical
Molecular Formula: C19H14N2O5
Molecular Weight: 350.33
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: O=C1NC(=O)N(Cc2ccccc2)C(=O)/C1=C\c1ccc2c(c1)OCO2
Standard InChI: InChI=1S/C19H14N2O5/c22-17-14(8-13-6-7-15-16(9-13)26-11-25-15)18(23)21(19(24)20-17)10-12-4-2-1-3-5-12/h1-9H,10-11H2,(H,20,22,24)/b14-8-
Standard InChI Key: AIQAOCWPVYYIGL-ZSOIEALJSA-N
Molfile:
RDKit 2D
26 29 0 0 0 0 0 0 0 0999 V2000
10.7496 -9.5004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.1582 -8.7913 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.9754 -8.7913 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.3840 -9.5004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.9754 -10.2095 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.1582 -10.2095 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.9324 -9.5004 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
12.3840 -8.0822 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
12.3840 -10.9144 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
10.7496 -10.9144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9324 -10.9144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5238 -11.6235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7066 -11.6235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.2980 -10.9144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7066 -10.2094 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5238 -10.2094 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.2012 -9.5004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9748 -12.2300 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.7221 -11.8956 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.6340 -11.0852 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
14.8356 -10.9144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.4270 -11.6235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.4270 -10.2095 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.6098 -10.2095 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.2012 -10.9144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.6098 -11.6235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 1 0
4 5 1 0
5 6 1 0
1 6 1 0
1 7 2 0
3 8 2 0
5 9 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 16 1 0
11 16 2 0
10 11 1 0
6 10 1 0
18 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
18 22 1 0
23 24 1 0
24 25 2 0
25 26 1 0
22 26 2 0
21 23 2 0
17 24 1 0
4 17 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 350.33Molecular Weight (Monoisotopic): 350.0903AlogP: 2.08#Rotatable Bonds: 3Polar Surface Area: 84.94Molecular Species: NEUTRALHBA: 5HBD: 1#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 7.08CX Basic pKa: ┄CX LogP: 2.35CX LogD: 1.87Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.68Np Likeness Score: -0.87
References 1. Rechfeld F, Gruber P, Kirchmair J, Boehler M, Hauser N, Hechenberger G, Garczarczyk D, Lapa GB, Preobrazhenskaya MN, Goekjian P, Langer T, Hofmann J.. (2014) Thienoquinolines as novel disruptors of the PKCε/RACK2 protein-protein interaction., 57 (8): [PMID:24712764 ] [10.1021/jm401605c ]